Mesenchymal stem cell therapy for chronic major ischemic stroke
The STARTING-2 study found no evidence to suggest that treatment with intravenous preconditioned autologous mesenchymal stem cells (MSCs) improves 90-day modified Rankin Scale (mRS) outcomes in patients with chronic ischemic stroke.
Why this matters
The potential application of stem cell therapy for chronic stroke is of keen interest.
A previous incarnation of the STARTING-2 study (STARTING) used fetal bovine serum (FBS) to expand autologous MSCs for treatment but encountered efficacy limitations.
Using autologous patient serum rather than FBS to expand MSCs could possibly decrease rates of cell senescence and improve therapeutic efficacy of MSC therapy for chronic stroke.